Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, announced today that the FDA has granted orphan drug designation (ODD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback